400 Participants Needed

EYP-1901 vs Aflibercept for Age-Related Macular Degeneration

(wAMD Trial)

Recruiting at 74 trial locations
RR
Overseen ByRamiro Ribeiro, MD, PhD
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: EyePoint Pharmaceuticals, Inc.
Must be taking: Anti-VEGF injections
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you are already receiving anti-VEGF injections for your condition, you may need to continue them as part of the study.

What data supports the effectiveness of the drug Aflibercept for treating age-related macular degeneration?

Research shows that Aflibercept is effective in treating age-related macular degeneration, with studies reporting positive outcomes in visual improvement and reduced need for frequent injections.12345

Is EYP-1901 or Aflibercept safe for humans?

Studies on aflibercept (also known as Eylea or Zaltrap) show it is generally safe for treating eye conditions like age-related macular degeneration and diabetic macular edema, with no major adverse events reported in the short term.678910

How is the drug EYP-1901 (Aflibercept) unique for treating age-related macular degeneration?

EYP-1901 (Aflibercept) is unique because it acts as a decoy receptor for VEGF, a protein that promotes abnormal blood vessel growth in the eye, and it requires fewer injections compared to some other treatments, potentially reducing the treatment burden for patients.911121314

Eligibility Criteria

This trial is for individuals with wet Age-Related Macular Degeneration (wAMD), either new or previously treated. Participants must have a certain level of vision, measured by the ETDRS letter score, and if previously treated, they should have had at least two anti-VEGF injections in the past six months.

Inclusion Criteria

I've had at least 2 eye injections for wet AMD in the last 6 months.
My vision in the study eye ranges from 20/32 to 20/200 with correction.
I have been diagnosed with wet AMD in one eye, regardless of prior treatments.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either EYP-1901 or Aflibercept for the treatment of wet AMD

56 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Extension

Participants may continue to receive treatment for up to 2 years

Additional 48 weeks

Treatment Details

Interventions

  • Aflibercept
  • EYP-1901
Trial OverviewThe study compares EYP-1901 to Aflibercept over two years to see which is more effective for wAMD. It's a phase 3 trial where participants are randomly assigned treatments and neither they nor the researchers know who gets which treatment (double-masked).
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: EYP-1901 2686 µgExperimental Treatment1 Intervention
EYP-1901
Group II: AfliberceptActive Control1 Intervention

Aflibercept is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Eylea for:
  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
🇪🇺
Approved in European Union as Eylea for:
  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)
🇺🇸
Approved in United States as Zaltrap for:
  • Metastatic Colorectal Cancer

Find a Clinic Near You

Who Is Running the Clinical Trial?

EyePoint Pharmaceuticals, Inc.

Lead Sponsor

Trials
19
Recruited
2,700+

Findings from Research

In a study of 28 patients with newly diagnosed wet age-related macular degeneration (ARMD), treatment with aflibercept showed significant efficacy, with 89.3% of eyes maintaining or improving visual acuity after one year.
The treatment was safe, with no recorded complications, and resulted in a substantial reduction in central retinal thickness, indicating effective management of the condition.
ONE-YEAR FOLLOW-UP OUTCOMES OF TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION WITH AFLIBERCEPT.Klimešová, YM., Penčák, M., Straňák, Z., et al.[2019]
In a study of 36 patients with neovascular age-related macular degeneration (AMD), aflibercept treatment resulted in a significant improvement in visual acuity, with a mean gain of nearly 16 letters after an average follow-up of 12 months.
The treatment was safe and effective, with 97.3% of patients maintaining their vision, and a decrease in central macular thickness, indicating a positive impact on the condition.
The results of aflibercept therapy as a first line treatment of age-related macular degeneration.Unsal, E., Cubuk, MO.[2023]
In a study of 1027 treatment-naïve patients with neovascular age-related macular degeneration, both ranibizumab and aflibercept showed similar improvements in visual acuity after one year, indicating their comparable efficacy.
Patients treated with aflibercept required 15% fewer injections than those treated with ranibizumab, suggesting that aflibercept may offer a more convenient treatment regimen without compromising visual outcomes.
Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.Rasmussen, A., Sander, B., Larsen, M., et al.[2022]

References

1.Czech Republicpubmed.ncbi.nlm.nih.gov
ONE-YEAR FOLLOW-UP OUTCOMES OF TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION WITH AFLIBERCEPT. [2019]
The results of aflibercept therapy as a first line treatment of age-related macular degeneration. [2023]
Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections. [2022]
HIGH-DOSE HIGH-FREQUENCY AFLIBERCEPT FOR RECALCITRANT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. [2019]
Intravitreal aflibercept (A-IVI) for the treatment of neovascular age-related macular degeneration (nv-AMD): one year experience. [2019]
SHORT-TERM SAFETY PROFILE OF INTRAVITREAL ZIV-AFLIBERCEPT. [2022]
Long-term safety and efficacy of ziv-aflibercept in retinal diseases. [2022]
Vision-Related Quality of Life in Patients with Diabetic Macular Edema Treated with Intravitreal Aflibercept: The AQUA Study. [2020]
Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration. [2015]
Aflibercept for Diabetic Macular Edema in Real-Life Practice in GREece: Three-Year Outcomes of the ADMIRE Study. [2023]
Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. [2021]
12.United Statespubmed.ncbi.nlm.nih.gov
FLATTENING OF A TREATMENT-RESISTANT RETINAL PIGMENT EPITHELIAL DETACHMENT AFTER A SINGLE INTRAVITREAL INJECTION OF ZIV-AFLIBERCEPT. [2017]
Intravitreal Ziv-Aflibercept: A Comprehensive Review. [2019]
Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion. [2021]